Inaladuo Accuhaler

Fluticasone propionate and salmeterol, the active ingredient in Inaladuo Accuhaler, is an inhaled corticosteroid/long‑acting β2‑agonist (ICS/LABA) combination presented as a dry powder inhaler for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) as a maintenance therapy in adults and adolescents, helping to control inflammation and keep airways open. The device delivers a consistent dose of medication to the lungs, reducing airway inflammation and maintaining bronchodilation.

GNH USA supplies Inaladuo Accuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inaladuo Accuhaler, an inhaled corticosteroid/long‑acting β2‑agonist (ICS/LABA) combination, is used for maintenance therapy in obstructive airway diseases.

Asthma: improves symptom control and reduces the frequency of exacerbations in patients requiring daily maintenance therapy. Chronic obstructive pulmonary disease (COPD): enhances lung function, decreases breathlessness and lowers the risk of COPD exacerbations.

Inhaled use of Inaladuo Accuhaler may be associated with several adverse reactions.

Common Side Effects: - Oral thrush (candidiasis): fungal infection of the mouth or throat. - Hoarseness or dysphonia: voice changes due to local steroid effect. - Cough or throat irritation: mild irritation after inhalation. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing requiring medical attention. - Adrenal suppression: reduced cortisol production with prolonged high‑dose use. - Allergic reactions: rash, urticaria or anaphylaxis.

When prescribing Inaladuo Accuhaler, consider the following precautions.

Assess infection risk: monitor for oral candidiasis and treat promptly. Use spacer or rinse mouth: reduce local steroid effects and improve drug delivery. Monitor lung function: adjust therapy based on symptom control and spirometry results. Avoid abrupt discontinuation: taper if long‑term high‑dose therapy is needed. Store at ambient temperature: keep inhaler below 25 °C, protect from moisture and direct sunlight.

Inaladuo Accuhaler may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic steroid exposure. - Non‑selective beta‑blockers: can reduce the bronchodilator effect of salmeterol. - MAO inhibitors or tricyclic antidepressants: may increase cardiovascular adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia risk when combined with a β2‑agonist. - Theophylline: may increase the likelihood of tachycardia and tremor.